TRex Bio Filed for Initial Public Offering

The biotech firm plans to raise up to $133.3 million through its upcoming initial public offering.

Updated on Oct. 5, 2026 in Biotech

Bold flat-color editorial illustration featuring a clinical laboratory vial, representing the biotech industry and medical research investment. — Biotech firm TRex Bio has filed for an initial public offering, aiming to raise $133.3 million to accelerate clinical development of treatments for autoimmune and inflammatory diseases. AI Illustration. Upload story photo >

Live Poll

Is now a good time for you to invest in individual biotech stocks?

TRex Bio has officially filed paperwork for an initial public offering to advance its work on treatments for autoimmune and inflammatory diseases. The company intends to raise up to $133.3 million by marketing 8.3 million shares.

Why it matters

This move provides the necessary capital to scale the research and clinical development of potential therapies for patients suffering from inflammatory conditions. It signals a significant milestone in the growth of the company as it transitions to a publicly traded entity.

TRex Bio is bringing 8.3 million shares to market with an estimated price range of $14 to $16 each. The firm is currently focused on developing therapeutic interventions for complex autoimmune and inflammatory diseases.

The players

TRex Bio

TRex Bio is a biotechnology company focused on developing new therapies to treat various autoimmune and inflammatory diseases.

The details

The biotech company specializes in the development of treatments for autoimmune and inflammatory diseases, areas that require significant long-term investment. By filing these registration documents, the firm moves closer to entering the public markets to secure funding for its research pipeline.

The company filed the IPO registration document on Monday.

The Tech Race

This filing reflects a broader trend of biotech companies returning to public markets to secure capital for long-term drug development pipelines. It highlights the competitive pressure to secure funding before advancing experimental therapies through the clinical trial process.

While the IPO primarily affects institutional and retail investors interested in the biotech sector, the success of this offering could accelerate the pace of research for new autoimmune treatments. Investors should monitor the final pricing and market debut to assess the valuation of the firm compared to current industry standards.

The takeaway

The successful execution of this IPO will determine the scale of resources available for upcoming clinical studies. Investors and observers should watch for the final pricing to understand how the market currently values emerging therapeutic research.